WO2009078444A1 - 炎症性腸疾患の予防または治療剤 - Google Patents

炎症性腸疾患の予防または治療剤 Download PDF

Info

Publication number
WO2009078444A1
WO2009078444A1 PCT/JP2008/072999 JP2008072999W WO2009078444A1 WO 2009078444 A1 WO2009078444 A1 WO 2009078444A1 JP 2008072999 W JP2008072999 W JP 2008072999W WO 2009078444 A1 WO2009078444 A1 WO 2009078444A1
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
bowel disease
pharmaceutical composition
preventive
therapeutic agent
Prior art date
Application number
PCT/JP2008/072999
Other languages
English (en)
French (fr)
Inventor
Tomohisa Ninomiya
Takashi Shishikura
Mitsuhiro Uchida
Sho Takahata
Yukari Hoshina
Ken-Ichi Kawano
Original Assignee
Meiji Seika Kaisha, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha, Ltd. filed Critical Meiji Seika Kaisha, Ltd.
Priority to JP2009510216A priority Critical patent/JP4343268B2/ja
Priority to EP08863206A priority patent/EP2123277B1/en
Priority to RU2010129447/15A priority patent/RU2469724C2/ru
Priority to PL08863206T priority patent/PL2123277T3/pl
Priority to CN2008801215910A priority patent/CN101903027B/zh
Priority to BRPI0821302A priority patent/BRPI0821302A8/pt
Priority to AT08863206T priority patent/ATE497386T1/de
Priority to DE602008004820T priority patent/DE602008004820D1/de
Priority to AU2008339393A priority patent/AU2008339393A1/en
Priority to DK08863206.2T priority patent/DK2123277T3/da
Priority to CA2709119A priority patent/CA2709119C/en
Priority to US12/449,371 priority patent/US7858612B2/en
Publication of WO2009078444A1 publication Critical patent/WO2009078444A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

　本発明は、７，８－ジメトキシ－４（５Ｈ），１０－ジオキソ－１Ｈ－１，２，３－トリアゾロ［４，５－ｃ］［１］ベンゾアゼピン、そのプロドラッグ、好ましくはプロドラッグとしての２－（１－イソプロポキシカルボニルオキシ－２－メチルプロピル）－７，８－ジメトキシ－４（５Ｈ），１０－ジオキソ－２Ｈ－１，２，３－トリアゾロ［４，５－ｃ］［１］ベンゾアゼピン、またはそれら薬理学的に許容される塩を含んでなる、炎症性腸疾患の予防または治療用医薬組成物に関する。本発明による医薬組成物は、炎症性腸疾患の予防および治療に有効で、かつ副作用が少ないものである。特に、本発明による医薬組成物は、既存の治療薬に抵抗性を示す重症例に対しても強い予防効果と治療効果を示しうる。
PCT/JP2008/072999 2007-12-18 2008-12-17 炎症性腸疾患の予防または治療剤 WO2009078444A1 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2009510216A JP4343268B2 (ja) 2007-12-18 2008-12-17 炎症性腸疾患の予防または治療剤
EP08863206A EP2123277B1 (en) 2007-12-18 2008-12-17 Preventive or therapeutic agent for inflammatory bowel disease
RU2010129447/15A RU2469724C2 (ru) 2007-12-18 2008-12-17 Профилактическое или терапевтическое вещество при воспалительных болезнях кишечника
PL08863206T PL2123277T3 (pl) 2007-12-18 2008-12-17 Środek zapobiegawczy lub terapeutyczny do leczenia choroby zapalnej jelit
CN2008801215910A CN101903027B (zh) 2007-12-18 2008-12-17 用于炎症性肠疾病的预防剂或治疗剂
BRPI0821302A BRPI0821302A8 (pt) 2007-12-18 2008-12-17 Composição farmacêutica, método para prevenir ou tratar doenças do intestino inflamatórias, e, uso de um composto
AT08863206T ATE497386T1 (de) 2007-12-18 2008-12-17 Vorbeuge- oder heilmittel für entzündliche darmerkrankungen
DE602008004820T DE602008004820D1 (de) 2007-12-18 2008-12-17 Vorbeuge- oder heilmittel für entzündliche darmerkrankungen
AU2008339393A AU2008339393A1 (en) 2007-12-18 2008-12-17 Preventive or therapeutic agent for inflammatory bowel disease
DK08863206.2T DK2123277T3 (da) 2007-12-18 2008-12-17 Forebyggende eller terapeutisk middel mod inflammatorisk tarmsygdom
CA2709119A CA2709119C (en) 2007-12-18 2008-12-17 Preventive or therapeutic agent for inflammatory bowel diseases
US12/449,371 US7858612B2 (en) 2007-12-18 2008-12-17 Therapeutic agent for inflammatory bowel diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007326543 2007-12-18
JP2007-326543 2007-12-18

Publications (1)

Publication Number Publication Date
WO2009078444A1 true WO2009078444A1 (ja) 2009-06-25

Family

ID=40795557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072999 WO2009078444A1 (ja) 2007-12-18 2008-12-17 炎症性腸疾患の予防または治療剤

Country Status (16)

Country Link
US (1) US7858612B2 (ja)
EP (1) EP2123277B1 (ja)
JP (1) JP4343268B2 (ja)
KR (1) KR101216756B1 (ja)
CN (1) CN101903027B (ja)
AT (1) ATE497386T1 (ja)
AU (1) AU2008339393A1 (ja)
BR (1) BRPI0821302A8 (ja)
CA (1) CA2709119C (ja)
DE (1) DE602008004820D1 (ja)
DK (1) DK2123277T3 (ja)
ES (1) ES2360461T3 (ja)
PL (1) PL2123277T3 (ja)
PT (1) PT2123277E (ja)
RU (1) RU2469724C2 (ja)
WO (1) WO2009078444A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7332167B2 (ja) 2018-07-28 2023-08-23 スージョウ・ファルマヴァン・カンパニー・リミテッド 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用
JP2022501315A (ja) * 2018-08-15 2022-01-06 ファルマシル・アクチボラグ 病的炎症の新しい医療

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018130A1 (fr) 1993-12-28 1995-07-06 Meiji Seika Kabushiki Kaisha Derives tricycliques de benzazepine et benzothiazepine
WO1997000258A1 (fr) * 1995-06-15 1997-01-03 Meiji Seika Kabushiki Kaisha Composes de benzazepine tricyclique
WO1999016770A1 (fr) 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Derives de triazolobenzazepine tricyclique, leur procede de production et antiallergique
JP2007326543A (ja) 2006-06-07 2007-12-20 Giichi Ishikura 排気ガス利用による保温ダンプ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637654A5 (en) * 1977-02-18 1983-08-15 Takeda Chemical Industries Ltd Triazolobenzazepine derivatives, process for their preparation and pharmaceutical preparations containing them
PE20001566A1 (es) * 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
CA2430363C (en) * 2000-12-01 2010-04-13 Guilford Pharmaceuticals Inc. Compounds and their uses
ES2312650T3 (es) * 2001-12-26 2009-03-01 Meiji Seika Kaisha Ltd. Nuevo derivado de triazolobenzazepina triciclica cristalina.
WO2004113451A1 (ja) * 2003-06-20 2004-12-29 Meiji Seika Kaisha, Ltd. 難溶性物質と水溶性高分子との共沈物およびその製造方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018130A1 (fr) 1993-12-28 1995-07-06 Meiji Seika Kabushiki Kaisha Derives tricycliques de benzazepine et benzothiazepine
US5686442A (en) 1993-12-28 1997-11-11 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives
JP3290664B2 (ja) 1993-12-28 2002-06-10 明治製菓株式会社 ３環性ベンゾアゼピンおよびベンゾチアゼピン誘導体
WO1997000258A1 (fr) * 1995-06-15 1997-01-03 Meiji Seika Kabushiki Kaisha Composes de benzazepine tricyclique
WO1999016770A1 (fr) 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Derives de triazolobenzazepine tricyclique, leur procede de production et antiallergique
JP3188482B2 (ja) 1997-09-29 2001-07-16 明治製菓株式会社 三環性トリアゾロベンゾアゼピン誘導体およびその製造法並びに抗アレルギー剤
US6372735B1 (en) 1997-09-29 2002-04-16 Meiji Seika Kaisha, Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
JP2007326543A (ja) 2006-06-07 2007-12-20 Giichi Ishikura 排気ガス利用による保温ダンプ

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
AKIHIDE KODA: "History and Present Situation of Anti-allergic Agents", 1988, LIFE SCIENCE CO., LTD., article "History and Present Situation of Anti-allergic Agents", pages: 32 - 39
BINDER V ET AL., DISODIUM CROMOGLYCATE IN THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE, vol. 22, no. 1, 1981, pages 55 - 60
BUCKELL NA ET AL.: "Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis", GUT, vol. 19, no. 12, 1978, pages 1140 - 1143
CRONSTEIN BN; MONTESINOS MC; WEISSMAN G: "Salitylates and sulfasalazine, but not glucocorticoid, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 NF-KB", PROC. NATI. ACAD. SCI. USA, vol. 96, no. 11, 25 May 1999 (1999-05-25), pages 6377 - 6381
CROTTY B; JEWELL DP: "Drug therapy of ulcerative colitis", BR. J. CLIN. PHARMC., vol. 34, no. 3, 1992, pages 189 - 198
HIBI N., INTRODUCTION JAPANESE J. CLIN. MED., vol. 63, no. 5, 2005, pages 741 - 743
HIDEO YAMAZAKI ET AL.: "Kaiyosei Daichoen ni Taisuru Ko Allergy-zai no Koka", GASTROENTEROLOGY, vol. 15, no. 2, 1991, pages 135 - 140 *
ISHIZAKA K.; ISHIZAKA T; HORNBROOK MM: "Physico-Chemical Properties of Human Reaginic Antibody IV: Presence of a Unique Immunoglobulin as a Carrier of Reaginic Activity", JOURNAL OF IMMUNOLOGY, vol. 97, no. 1, 1966, pages 75 - 85
JOHN L. WALLACE ET AL., GASTROENTEROLOGY, vol. 96, 1989, pages 29 - 36
KEIICHI MITSUYAMA: "Kaiyosei Daichoen Chiryo no Saikin no Wadai", JAPANESE JOURNAL OF GASTROENTEROLOGY, vol. 97, no. 1, 2000, pages 10 - 20, XP008110464 *
KEIICHI MITSUYAMA; MAKOTO TOYONAGA; MICHIO SATA: "Inflammatory Bowel Diseases", 2005, SAISHIN-IGAKU, article "Pathology and Pathophysiology of Inflammatory Bowel Diseases", pages: 28 - 36
KOJI URAUSHIBARA; MAMORU WATANABE: "Inflammatory Bowel Diseases", 2005, SAISHIN-IGAKU, article "Concept, Definition and Epidemiology of Inflammatory Bowel Diseases", pages: 9 - 15
KUHN R ET AL.: "Interieukin-10-deficient mice develop chronic enterocolitis", CELL, vol. 75, no. 2, 1993, pages 263 - 274
MA A ET AL.: "T cells, but not B cells, are required for bowel inflammation in interleukin-2-deficient mice", J. EXP. MED., vol. 182, no. 5, 1995, pages 1567 - 1572
OHKUSA T; NOMURA T; SATO N.: "The role of bacterial infection in the pathogenesis of inflammatory bowel disease.", INTERNATIONAL MEDICINE, vol. 43, no. 7, 2004, pages 534 - 539
SHUICHI UENO: "Mechanism of Body and Allergy", 1998, NIPPON JITSUGYO PUBLISHING
TADAO BABA: "inflammatory bowel diseases", RECENT TREND. MATSUSHITA MEDICAL JOURNAL, vol. 39, no. 1, 2000, pages 1 - 14

Also Published As

Publication number Publication date
DK2123277T3 (da) 2011-03-14
US7858612B2 (en) 2010-12-28
JPWO2009078444A1 (ja) 2011-04-28
RU2010129447A (ru) 2012-01-27
BRPI0821302A8 (pt) 2015-12-08
JP4343268B2 (ja) 2009-10-14
PL2123277T3 (pl) 2011-08-31
KR20100094576A (ko) 2010-08-26
EP2123277B1 (en) 2011-02-02
CA2709119A1 (en) 2009-06-25
PT2123277E (pt) 2011-04-20
KR101216756B1 (ko) 2012-12-28
RU2469724C2 (ru) 2012-12-20
DE602008004820D1 (de) 2011-03-17
EP2123277A4 (en) 2010-01-06
ES2360461T3 (es) 2011-06-06
AU2008339393A1 (en) 2009-06-25
CA2709119C (en) 2013-08-06
CN101903027B (zh) 2013-06-12
ATE497386T1 (de) 2011-02-15
CN101903027A (zh) 2010-12-01
BRPI0821302A2 (pt) 2015-06-16
EP2123277A1 (en) 2009-11-25
US20100130475A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
IL264796B (en) History of 6,23-metabolized bile acid, pharmaceutical preparations acceptable in a pharmacy and compounds for use in a method for treating or preventing a disease
WO2007041368A3 (en) Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
WO2006086456A3 (en) Combination of organic compounds
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
WO2006131874A3 (en) Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2007092469A3 (en) Combination of organic compounds
EP2420233A3 (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2005107752A3 (en) Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
WO2007006790A3 (en) Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
WO2009078444A1 (ja) 炎症性腸疾患の予防または治療剤
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2008022807A3 (en) Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880121591.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2009510216

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008863206

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449371

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08863206

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008339393

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2709119

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4296/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008339393

Country of ref document: AU

Date of ref document: 20081217

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107015613

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010129447

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0821302

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100618